Literature DB >> 8390534

Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes.

F G Snijdewint1, P Kaliński, E A Wierenga, J D Bos, M L Kapsenberg.   

Abstract

PGE2 is a well known immunomodulator that has multiple effects on the immune system. We demonstrate that PGE2 selectively and dose dependently inhibits IL-2 and IFN-gamma production by mitogenically stimulated human PBL and CD4+ TLC, although at low concentrations IL-4 production is not affected and IL-5 production is even up-regulated. In the tested TLC, PGE2 induced a dramatic elevation (up to 85-fold) of the intracellular cAMP levels. The action of PGE2 may, therefore, be associated with elevation of intracellular cAMP levels, affecting IL-4 and IL-5 differentially from IL-2 and IFN-gamma production. To test this hypothesis we investigated cytokine production by TLC in the absence or presence of agents that affect cAMP levels, either directly (2'-O-dibutyrylcAMP) or through activation of adenylate cyclase (forskolin) or by blocking of phosphodiesterase (3-isobutyl-1-methyl-xanthine). Similar to PGE2, forskolin, 2'-O-dibutyrylcAMP, and 3-isobutyl-1-methyl-xanthine induced inhibition of IL-2 production by TLC and up-regulation of IL-5 production. However, in contrast to PGE2, these agents suppressed IL-4 production although IFN-gamma production was only moderately affected. No significant differences were found between intracellular cAMP levels of mitogenically stimulated Th1 cell clones, which predominantly secrete IL-2 and IFN-gamma, and those of Th2 cell clones, which mainly secrete IL-4 and IL-5. Our results indicate that PGE2 selectively modulates cytokine secretion profiles of human T cells and that elevation of cAMP levels has an important, but possibly not exclusive, regulatory role in this phenomenon.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390534

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  112 in total

Review 1.  Th1/Th2 balance in atopy.

Authors:  T Biedermann; M Röcken
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis.

Authors:  M Cutolo; A Sulli; C Pizzorni; B Seriolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

3.  Production of prostaglandins and leukotrienes by pathogenic fungi.

Authors:  Mairi C Noverr; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

4.  Gram-negative, but not Gram-positive, bacteria elicit strong PGE2 production in human monocytes.

Authors:  Christina C Hessle; Bengt Andersson; Agnes E Wold
Journal:  Inflammation       Date:  2003-12       Impact factor: 4.092

Review 5.  Early life precursors, epigenetics, and the development of food allergy.

Authors:  Xiumei Hong; Xiaobin Wang
Journal:  Semin Immunopathol       Date:  2012-07-10       Impact factor: 9.623

Review 6.  Role of prostanoids in gastrointestinal cancer.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

7.  Characterization of prostaglandin E2 production by Candida albicans.

Authors:  John R Erb-Downward; Mairi C Noverr
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

Review 8.  Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3.

Authors:  Laurence S Harbige
Journal:  Lipids       Date:  2003-04       Impact factor: 1.880

9.  Role of antibiotics and fungal microbiota in driving pulmonary allergic responses.

Authors:  Mairi C Noverr; Rachael M Noggle; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

10.  Combined treatment with interleukin-12 and indomethacin promotes increased resistance in BALB/c mice with established Leishmania major infections.

Authors:  Jian Li; Udaikumar M Padigel; Phillip Scott; Jay P Farrell
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.